Prostaglandin receptor ligands: Recent patent activity

IDrugs

Volumn 3, Issue 9, 2000, Pages 1039-1052

  DeLong, Mitchell A ^a  

^a Procter and Gamble ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 18244374972     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (157)

1. Negishi M, Sugimoto Y, Ichikawa A: Molecular mechanisms of the diverse actions of prostanoid receptors. Biochim Biophys Acta (1995) 1259:109-120;
2. Collins PW, Djuric SW: Synthesis of therapeutically useful prostaglandin and prostacyclin analogs. Chem Rev (1993) 93:1533-1564.
3. Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Lumley P: Prostanoids and their receptors. In: Comprehensive Medicinal Chemistry: Membranes and Receptors. Emmett JC (Ed), (1990).
4. Coleman RA, Smith WL, Narumiya S: International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev (1994) 46(2):205-229.
5. Bito LZ: Prostaglandins, other Eicosanoids, and their derivatives as potential antiglaucoma agents. Curr Opin Ophthamol (1993) 4(11):44-50.
6. Coleman RA, Smith WL, Narumia S: Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev (1994) 46:205-229.
7. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Binding specificities of the prostanoid receptors. Br J Pharmacol (1997) 122:217-224.
8. 1 subtype. J Biol Chem (1995) 270:18910-18916.
9. Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM and Grygorczyk R: Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem (1994) 269:2632-2636.
10. Ichikawa A: Molecular aspects of the structures and functions of the prostaglandin E receptors. J Lipid Med Cell Signal (1996) 14: 83-87.
11. 2-α. Br J Pharm (1996) 117(6):1171-1180.
12. Corsini A, Folco GC, Fumagalli R: (5Z)-Carbacyclin discriminates between prostacyclin receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol (1987) 90:255-261.
13. Woodward DF, Gil DW, Chen J, Burk RM, Kedzie KM, Krauss AH-P: Emerging evidence for additional prostanoid receptor subtypes. Curr Top Pharmacol (1998) 4:153-162.
14. 3. N-S Arch Pharm (1998) 358(1):1713-1713.
15. 2α receptor associated protein (FPRP). Prostaglandins Leukotr Ess Fatty Acids (1996) 54(5):247-259.
16. Jakobsson PJ, Morgenstern R, Mancini J, FordHutchinson A, Persson B: Membrane-associated proteins in eicosanoid and glutathlone metabolism (MAPEG)-A widespread protein superfamily. Am J Resp Crit Care Med (2000) 161:20-24.
17. Abramovitz M, Adam M, Boie Y, Carriere MC, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, Metters KM: The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta (2000) 1483(2):285-293.
18. Lacombe P, Ruel R, Abamowitz M, Godbout C, Lamontagne S, Rochette S, Sawyer N, Stocco R, Tremblay MN, Metters KM, Labelle M: New class of biphenylene dibenzazocinones as potent ligands for the human EP, prostanoid receptor. ACS (1999) 218 New Orleans: MEDI 262.
19. 2 antagonist, and its analogs. J Med Chem (1996) 39: 609.
20. 1 prostanoid receptor. Bioorg Med Chem Lett (1999) 9:2699-2704.
21. Maruyama T, Koketsu M, Yamamoto H, Yamamoto K, Yamamoto LT, Hayashida KI, Ohuchida S, Kondo K: EP, receptor antagonists suppress tactile allodynia in rats. Prostaglandins Lipid Mediat (1999) 59:217.
22. AstraZeneca plc: AstraZeneca progresses key products and aims to double product portfolio value every five years. Press Release (1999) December 06.
23. 1 in infants with cyanotic congenital heart disease. J Pediat (1980) 97:834.
24. 2 induces regional remodeling changes in haversian envelope: A histomorphometric study of fractured ribs in beagles. Bone Miner (1986) 1:227.
25. 2 on production of new cancellous bone in the axial skeleton of ovariectomized rats. Bone (1990) 11:103.
26. 2. Prostaglandins (1984) 27:97.
27. Norrdin RW, Jee WSS, High WB: The role of prostaglandins in bone in vivo. Prost Leuk Ess Fatty Acids (1990) 41:139-149.
28. 4 in human osteoblast-like cells and 23 human tissues. J Bone Miner Res (1996) 11:337.
29. Hartke JR, Jankowsky ML, deLong MA, Soehner ME, Jee WSS, Lundy MW: Prostanoid FP agonists build bone in the ovariectomized rat. J Bone Min Res (1999) 14:207.
30. Lundy MW, deLong MA, Combs KS, Gross GJ, Soehner ME, Hartke JR: Restoration of cancellous architecture and increased bone strength in aged osteopenic rats treated with fluprostenol. J Bone Min Res (1999) 14:401.
31. 1. analogs as potent and selective ligands for the human FP receptor. J Med Chem (2000) 43 (5)945-952.
32. 4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res (2000) 15 (2)218-227.
33. 3-mediated effects on resting zone chondrocytes. J Cell Physiol (2000) 182 (2)196-208.
34. Narumiya S: Roles of prostanoids in health and disease, lessons from receptor-knockout mice. Int Congr Ser (1999) 1181 261-269.
35. 2. Am J Physiol (1999) 46(3):924-930.
36. Vayssairat M: Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. J Rheumatol (1999) 26 (10)2173-2178.
37. Murakami T, Sawada K: Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease. Arzneimittelforschung (1995) 45:991-994.
38. Hall A, Smith WHT: Clinprost. Teijin. Curr Opin Cardiovasc Pulm Renal Invest Drugs (1999) 1(5):605-610.
39. 2 receptor antagonist, ramatroban (BAY U3405), on inflammatory cells, chemical mediators and non-specific nasal hyperreactivity after allergen challenge in patients with perennial allergic rhinitis. Allergol Int (1998) 47(1):59-67.
40. Miyamoto T, Takishima T: A comparison in the efficacy and safety between ramatroban (BAY u 3405) and ozagrel-HCl for bronchial asthma: a phase III, multi-center, randomized, double-blind, group comparative study. Rinsho Iyaku (1997) 13:599-639.
41. Rampton DS, Carty E: Anti-inflammatory profile in vitro of ridogrel, a putative new treatment for inflammatory bowel disease. Gastroenterology (1999) 116:801.
42. McCullough PA: Ridogrel (Janssen). Curr Opin Anti-Inflamm Immunomod Invest Drugs (1999) 1 (3):265-276.
43. 2 receptor antagonists. Farumashia (1996) 32(10):1221-1225.
44. 2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl) sulfonyl]amino] methyl] cyclopentyl] methyl] benzeneacetate LBC-2853. Arzneimittelforschung (1994) 44(11):1196-1202.
45. 2 receptor antagonist, S18886, decreases atherosclerotic lesions and serum intracellular adhesion molecule-1 in the Apo E knockout mouse. Circulation (1998) 98:115.
46. 2. Thromb Haemostasis (1997): 693.
47. 2 receptor antagonist 2-335 and related compounds. AFMC (1995) 95:53.
48. 2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophth (1988) 105:30-34.
49. Merrill Lynch: Pharmaceutical Biotechnology and Medical Device Bulletin. Analyst Report (1999) June 17.
50. Van Denburgh AM, Laibovitz RA, Felix C: A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure. Invest Ophth Vis Sci (1999) 40:62420-62420.
51. Chen J, Woodward DF, Gil DW, Messier T, Marshall K, Senior J: AGN 191129: A neutral prostaglandin F-2 α (PGF2α) analog that lacks the mitogenic and uterotonic effects typical of FP receptor agonists. Invest Ophth Vis Sci (1999) 40:62420-62420.
52. 3H]9 beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol (1999) 51(60):685-94.
53. Garadi R, Silver L, Landry T, Turner FD: Travoprost: A new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure. Invest Ophth Vis Sci (1999) 40(4):78181.
54. Dean TR, Barnes GE, Li B, Chandler ML: Improvement of optic nerve head blood flow after one-week topical treatment with travoprost (AL-06221) in the rabbit. Invest Ophth Vis Sci (1999) 40(4):88563.
55. 2α (FP) receptor. J Pharmacol Exp Ther (1999) 290 (31):1278-1284.
56. 2 receptor. J Ocul Pharmacol Therap (1995) 11(3)447-454.
57. Karim SMM, Adaikin PG, Kottegoda SR: Prostaglandins and human respiratory tract smooth muscle: Structure activity relationship. Adv Prostaglandin Thromboxane Leukot Res (1980) 7:969-980.
58. Maw GN: Pharmacological therapy for the treatment of erectile dysfunction. Annu Rep Med Chem (1999) 34:71-80.
59. 1 (Nexmed). Drugs R&D (1999) 2(6):413-414.
60. Matsumura H: Prostaglandins and sleep. Saishin No To Shinkei Kagaku Shirizu (1998) 10:79-89.
61. Tomita Y, Maeda K, Tagami H: Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigm Cell Res (1992) 5(Part2):357-61.
62. 2 antagonists. Asia Pacific J Pharmacol (1994) 9:163-171.
63. Flisiak R, Prokopowicz D: Effect of misoprostol on the course of viral hepatitis B. Hepato-Gastroenterology (1997) 44(17):1419-1425.
64. Mihele D, Cristea E, Mihele D, Cocu F: The testing of the hepatoprotective action of some new synthetic prostaglandins. Farmacia (Bucharest) (1999) 47 (5):43-58.
65. Vengerovsky AI, Baturina NO, Saratikov AS: Hepatoprotective action of prostaglandins. Eksp Klin Farmakol (1997) 60(5):78-82.
66. Clissold D: The potential for prostaglandin pharmaceuticals. Spec Publ - R Soc Chem (1999) 244:115-129.
67. 4. US-05605814 (1997).
68. MERCK FROSST CANADA INC (Abramovitz M, Boie Y, Metters K, Sawyer N, Slipetz DM): Prostaglandin receptor DP. WO-09623066 (1996), US-05958723 (1999).
69. MERCK FROSST CANADA INC (Abramovitz M, Boie Y, Grygorczyk R, Metters K, Rushmore TH, Slipetz DM): DNA encoding prostaglandin receptor IP. WO-09509872 (1995).
70. 2. WO-09506664 (1995), US-05759789 (1998).
71. 1. WO-09428125 (1994), US-05985597 (1999); US-6031079 (2000).
72. MERCK-FROSST CANADA Inc (Abramovitz M, Grygorczyk R, Metters K, Nguyen T, Rushmore TH, Slipetz D): Purified prostaglandin receptor FP. US-05840847 (1998), US-05869281 (1999).
73. 3 and DNA encoding it. WO-09500552 (1995).
74. ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (Schuster VL, Lu R): Human prostaglandin transporter. US-05792851 (1998).
75. TAISHO PHARMACEUTICAL CO LTD (Ohara O, Nagase T, Nomura N Takayama K, Toyoda H, Yoshimoto M): Novel gene and protein PGTH encoded thereby. WO-00009557 (2000).
76. GD SEARLE & CO (Mueller RA): 8-chlorodibenz [b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenyl sulfinyl-, and phenylsulfonyl)alkanoyl] hydrazides. US-04704386 (1987).
77. GD SEARLE & CO (Chandrakumar NS, Hagen TJ, Pitzele BS, Tsymbalov S, Hallinan EA): 2, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use. US-05719140 (1998).
78. GD SEARLE & CO (Hallinan EA, Hagen TJ, Husa RK, Tsymbalov S, Van Hoeck JC, Lee AC): Substituted dibenzoxazepine compounds and methods for treating osteoporosis and ischemia. US-05576315 (1996).
79. MERCK FROSST CANADA AND CO (Gareau Y, LaBelle M, Juteau H, Gallant M, Lachance N, Belley M): Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment WO-09947497 (1999).
80. ONO PHARMACEUTICAL CO LTD (Ohuchida S, Nagao Y): New sulfonamide and carboxamide derivatives. WO-09827053 (1998).
81. THE UPJOHN CO (Lund JE, High WB): Treatment of osteoporosis with prostaglandins. US-04621100 (1986).
82. 2 agonists. WO-09827976 (1998).
83. PFIZER INC (Cameron KO, Lefker BA, Rosati RL, Thompson DD): Prostaglandin agonists and their use to treat bone disorders. WO-09919300 (1999); US-05703108 (1998).
84. PFIZER INC (Cameron KO, Dasilva-Jardine PA): Prostaglandin agonists. WO-09858911 (1998).
85. Pfizer Inc (Cameron KO, Ke HZ, Lefker BA, Rosati RL, Thompson DD): Prevention of loss and restoration of bone mass by certain prostaglandin agonists. WO-09828264 (1998).
86. ONO PHARMACEUTICAL CO (Maruyama T, Ohuchida S): New 3,7 dithiaprostanoic acid derivatives useful for the prevention and treatment of abnormal bone formation and neuronal cell death. EP-0855389 (1998).
87. ONO PHARMACEUTICAL CO (Maruyama T, Ohuchida S): ω-Substituted phenyl prostaglandin E derivatives and drugs containing the same as the active ingredient. WO-00015608 (2000).
88. ONO PHARMACEUTICAL CO LTD (Maruyama T, Ohuchida S): 5-Thia-ω-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient. WO-00003980 (2000).
89. PROCTER & GAMBLE (Hartke JR, Lundy M, deLong MA): Method of increasing bone volume using non-naturally-occurring FP agonists. WO-09912550 (1999).
90. THE PROCTER & GAMBLE COMPANY (Hartke JR, Lundy M, deLong MA): Method of increasing bone volume. WO-09912551 (1999).
91. THE PROCTER & GAMBLE COMPANY (Wos JA, deLong MA, Amburgy JS, De B, Dai G, Wang Y): Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists. WO-09912895 (1999); US-05977173 (1999).
92. THE PROCTER & GAMBLE COMPANY(deLong MA, Amburgey JS, De B, Dai G, Wang Y, Wos JA): Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists. WO-09912898 (1999).
93. THE PROCTER & GAMBLE COMPANY(Amburgey JS, De B, Dai G, Wang Y, Wos JA, deLong MA): Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists. WO-09912896 (1999), US-06048895 (2000).
94. 1α analogs. WO-09912897 (1999).
95. 1. analogs. WO-09912899 (1999).
96. THE PROCTER & GAMBLE COMPANY (deLong MA, Amburgey JS, Wos JA, De B, Soper DL): Preparation of C11-oximido prostaglandins to treat bone disorders and glaucoma. WO-09950241 (1999).
97. THE PROCTER & GAMBLE COMPANY (deLong MA, Amburgey JS, Wos JA, De B, Soper DL): Preparation of C11-oximido prostaglandins useful as FP agonists. WO-09950242 (1999).
98. 4 receptor antagonists GB-02330307 (1999).
99. QUEEN'S UNIVERSITY AT KINGSTON (Anastassiades T): Method and pharmaceutical composition for chondro-stimulation with a prostaglandin and TGF-β, optionally in conjunction with IGF-1. WO-09715319 (1997).
100. 2 antagonists. WO-00016760 (2000).
101. TORAY IND (Kurumatani H, Tamura M): Drugs for ameliorating pulmonary circulation. WO-09837895 (1998).
102. TORAY IND (Kurumatani H, Annoh S, Koike H): Drugs for relieving diabetic vascular lesion. WO-09840073 (1998).
103. 1 to treat peripheral vascular disease. WO-09925357 (1999).
104. FUJISAWA PHARMACEUTICAL CO (Taniguchi K, Nagano M, Hattori K, Tsubaki K, Okitsu O, Tabuchi S): 4,5-Diaryl oxazole derivatives. US-6025375 (2000).
105. FUJISAWA PHARMACEUTICAL CO (Taniguchi K, Hattori K, Tsubaki K, Okitsu O, Tabuchi S): 4,5-Diaryl oxazole derivatives. US-05972965 (1999).
106. ALLERGAN INC (Woodward DF): Method for effecting vasodilation with (1,5-inter) aryl prostaglandin derivatives. WO-09709049 (1997).
107. R-TECH UENO LTD (Ueno R, Ueno R, Oda T): Prostaglandins of the F series. US-05770759 (1998).
108. TORAY INDUSTRIES INC (Ohtake A, Hoshi K, Tsukamoto S, Takeda T, Yamada N, Matsumoto K, Ohno M, Ohno K): Benzene-condensed heterocyclic derivatives and their uses. US-06043264 (2000).
109. 2-receptor agonists as neuroprotective agents for the eye. WO-09926629 (1999).
110. PHARMACIA & UPJOHN COMPANY (Re RG): Solution compromising prostaglandin and benzyl alcohol. WO-09965527 (1999).
111. PHARMACIA & UPJOHN COMPANY (Stjernschantz JW, Bahram R): Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension. US-06030999 (2000).
112. PHARMACIA & UPJOHN COMPANY (Stjernschantz JW, Bahram R): Use of prostaglandins US-06031001 (2000).
113. ALCON LABORATORIES INC (Desantis L Jr, Sallee WL): Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma. WO-09408585 (1994).
114. ALCON LABORATORIES INC (Dean TR): Combinations of prostaglandins and miotics for lowering intraocular pressure. WO-09723226 (1997).
115. ALCON LABORATORIES INC (Dean TR, Hellberg MR, Sallee VL): Combinations of DP and FP type prostaglandins for lowering IOP. WO-09723225 (1997).
116. ALCON LABORATORIES INC (Dean TR, May JA): Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma. WO-09819680 (1998).
117. MERCK & CO INC (Ponticello GS, Sugrue MF): Ophthalmic compositions for treating ocular hypertension. WO-09853809 (1998).
118. MERCK & CO INC (Ponticello GS, Sugrue MF): Ophthalmic compositions for treating ocular hypertension. WO-00004898 (2000).
119. MERCK & CO INC (Ponticello GS, Sugrue MF): Ophthalmic compositions for treating ocular hypertension. WO-00004899 (2000).
120. ALLERGAN INC (Burk RM): Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents. WO-US-06037364 (2000).
121. ALCON LABORATORIES INC (Klimko PG, Bishop JE, Sallee VL, Zinke PW): Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension. US-05889052 (1999).
122. ALCON LABORATORIES (Klimko PG, Zinke PW): Cis-δ-4-analogs of prostaglandins as ocular hypotensives. US-05994397 (1999).
123. ALCON LABORATORIES (Selliah RD, Hellberg MR, Klimko PG, Sallee VL, Zinke PW): Tetrahydrofuran analogs of prostaglandins as ocular hypertensives. US-6025392 (2000).
124. ALCON LABORATORIES INC (Zinke PW, Bishop JE, Dean TR, Hellberg MR): Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy. WO-09821180 (1998).
125. ALCON LABORATORIES INC (Selliah RD): Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives. WO-09857930 (1998).
126. ALCON LABORATORIES INC (Feng Z, Hellberg MR): 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension. WO-09932441 (1999).
127. ALCON LABORATORIES INC (Zinke PW, Hellberg MR): 13-Thia prostaglandins for use in glaucoma therapy. WO-09839293 (1998).
128. ALCON LABORATORIES INC (Sallee VL, Hellberg MR, Klimko PG): 15-Ketal prostaglandins for the treatment of glaucoma or ocular hypertension. WO-09820881 (1998).
129. ALCON LABORATORIES INC (Selliah RD): 9-Oxa prostaglandin analogs as ocular hypotensives. WO-09857942 (1998).
130. ALCON LABORATORIES INC (Klimko PG, Hellberg MR): 15-Fluoro prostaglandins as ocular hypotensives. WO-09821181 (1998).
131. ALCON LABORATORIES INC (Sallee VL, Klimko PG, Hellberg RM, Zinke PW): 11-Halo prostaglandins for the treatment of glaucoma or ocular hypertension. WO-09820880 (1998).
132. ALCON LABORATORIES INC (Hellberg MR, Dean TR, Zinke PW, Selliah RD, Bishop JE): Use of 9-deoxy prostaglandin derivatives to treat glaucoma. WO-09610407 (1998).
133. ALCON LABORATORIES INC (Weiner AL, Airy SC, Yarborough C, Clifford JA, McCune WE): Prostaglandin product. WO-00003736 (2000).
134. ALCON LABORATORIES INC (Selliah RD, Hellberg MR, Sallee VL, Klimko PG, Zinke PW): Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives. WO-09723223 (1997).
135. 2-receptor agonists as agents for lowering intraocular pressure. WO-09519964 (1995).
136. PHARMACIA & UPJOHN AB (Stjernschantz JV, Resul BV, Lake SF): Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma. WO-09902165 (1999).
137. THE MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY OF NEW YORK (Podos SM, Mittag TW, Becker B): 8-lso prostaglandins for glaucoma therapy. WO-09850024 (1998); US-06037368 (2000).
138. SANTEN PHARMACEUTICAL CO LTD (Shirasawa E, Kageyama M, Mori N, Sakata K, Nakano T, Matsumura Y, Morizawa Y): Fluorinated prostaglandin derivatives and medicines. WO-09812175 (1998).
139. TORAY INDUSTRIES INC (Ochi Y, Yamada N, Wakita H, Moriyama M): Cervical maturing agent. WO-09913881 (1999).
140. HȮPITAL SAINTE-JUSTINE (Chemtob S, Peri KG, Potier M): Antagonists of G-protein-coupled receptor. WO-09932640 (1999).
141. VAISMAN JT: Method and composition for treatment of sexual dysfunction. WO-09922731 (1999).
142. GYURIK RJ: Composition and method for treating penile erectile dysfunction. WO-09965303 (1999).
143. VIVUS INC (Place VA, Wilson LF, Doherty PC, Hanamoto MS, Spivack AP, Gesundheit N, Bennett SR): Treatment of female sexual dysfunction. WO-09921562 (1999).
144. LAM PHARMACEUTICALS LLC (Drizen A, Rothbart P, Nath G): Drug preparations for treating sexual dysfunction. WO-00013664 (2000).
145. 2. combination for treating impotence and enhancing sexual arousal. WO-09930718 (1998).
146. 2 derivatives. WO-09933794 (1999).
147. 2 derivatives. EP-00860430 (1998).
148. ALBERTA CANCER BOARD (Patterson MC, Mirzayans R): Use of prostaglandins to treat ataxia telangiectasia. WO-09739754 (1997).
149. THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (Fullar BB): Enhancement of skin pigmentation by prostaglandins. WO-09800100 (1998).
150. TEIJIN LTD (Kataoka K, Minoshima T, Tsutsumi T, Hada T, Tanaka H, Morita T, Endo N): Prostaglandins and processes for producing them. US-05990346 (1999).
151. 1 methyl ester US-06013823 (2000).
152. MONSANTO CO (Tremont SJ, Collins PW): Gastro-specific prodrugs. US-06030959 (2000).
153. WINTHROP UNIVERSITY HOSPITAL (Maesaka JK): Methods of diagnosing salt wasting syndrome and Alzheimer's disease and methods of treating the same. WO-09964621 (1999).
154. TAISHO PHARMACEUTICAL CO (Tanami T, Kameo K, Yamada K, Okuyama S, Ono N): Sleep inducing agent WO-09961029 (1999).
155. SHIONOGI & CO LTD (Honma T): Compounds having [2.2.1]bicyclo skeleton. WO-09915502 (1999).
156. ONO PHARMACEUTICAL CO LTD (Ohuchida S, Maruyama T): 11,15-O-dialkylprostaglandin E derivatives, process for producing the same, and drugs containing the same as the active ingredient. WO-09834916 (1998).
157. UNIVERSITY COLLEGE LONDON MEDICAL SCHOOL AND ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (Stratton R, Black C, Martin GR, Carmichael DF): Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives. WO-00002450 (2000).